🔗 Share this article

A shadow economy for unapproved slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.

Investigational Treatment Gaining Popularity Online

Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Followers are encouraged to contact these profiles privately for source information, while also obtaining discount codes.

Thriving Trade on Messaging Platforms

Separately, a flourishing market exists on Telegram, where groups with thousands of members share comparison images, administration instructions and assertions of next-day British shipping. Sellers promote the drug there before redirecting buyers to other platforms for purchases.

Learning About Retatrutide

Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the next Ozempic.

Medical Experts Voice Concerns

However, physicians and pharmacists have cautions that the sale of what remains an unlicensed drug in the UK is worrisome and could lead to users administering products of unknown origin.

Several professionals stated the demand for retatrutide could be connected to the rising cost of licensed weight loss treatments such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several influencers attempt to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and distribution can still violate pharmaceutical, advertising, and consumer laws, risking penalties, legal action or imprisonment.

Platform Response and Content Removal

According to the social media company, the service has taken down problematic content and banned related keywords and query recommendations. The organization said it was dedicated to maintaining the service safe and investing in enhancing enforcement strategies.

Digital Trading Activities

Research also found groups with up to nine thousand members marketing the experimental drug using Telegram's integrated search feature, which functions like a online catalog. Typing “retatrutide” instantly displays channels with numerous of members, filled with images of weight loss, positive reviews and step-by-step instructions for mixing or injecting at home.

Within moments of entering one community, a seller shared contact information, where the majority of transactions take place. The seller sent an instruction manual and promised shipping within two days. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. None inquired about weight, medical conditions or past usage.

Product Information and Pricing

Inside these groups, messages display dark colored parcels with Royal Mail stickers, stating to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, prepared at home with sterile water, or ready-to-use injectors usually sold at £160 for 20 milligrams. When questioned how long a injector should last, vendors give conflicting responses ranging from a several days to “depends on your body”.

Platform Oversight and Security Measures

A spokesperson for the messaging service stated it actively moderated harmful content on its service including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are administering substances they can’t verify. Even if the science behind retatrutide is sound, these online versions may not contain what they claim,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent price rises for approved weight-loss medications such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But fake injections are extremely risky. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained.

Her team has already encountered patients harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or communication platforms is gambling with your health,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Producer Position

A representative from Eli Lilly said the substance was in third stage clinical trials and had not been reviewed or approved by any government authority globally. “Therefore at this point no one can sell [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a company experimental product not yet approved … may subject patients to potentially significant medical dangers”.